Determination of a Genotoxic NDMA Impurity Using the High-Resolution Agilent 6546 LC/Q-TOF in Ranitidine Drug Substance and Drug Products

Application Note Pharma & Biopharma Determination of NDMA Impurity in Ranitidine Using the Agilent 6470 Triple Quadrupole LC/MS Detection of regulated genotoxic impurity from the drug manufacturing process Authors Chander Mani and Saikat Banerjee Agilent Technologies, Inc. Abstract Impurities in…

Nitrosamine Impurities Application Guide Confidently Detect and Quantify Mutagenic Impurities in APIs and Drug Products Sartan-Based Losartan Valsartan Candesartan Telmisartan Metformin Ranitidine Nitrosamines are formed by chemical reactions that occur during API manufacturing whether from starting materials, intermediates, reactants, reuse…

APPLICATION NOTE 73814 HRAM LC-MS method for the determination of nitrosamine impurities in drugs Authors: Hao Yang, Thermo Fisher Scientific, San Jose, CA, US Jon Bardsley, Thermo Fisher Scientific, Hemel Hempstead, UK Min Du, Thermo Fisher Scientific, Boston, MA, US…

NDMA impurity in Ranitidine / LCMSTM-9030 Application News Detection and Quantitation of NDMA Impurity in Ranitidine Drug Substances and Products by LC-HRMS on LCMS-9030 Zhe Sun and Zhaoqi Zhan User Benefits  Determination of NDMA in ranitidine API and drug…